RAF1 and cancer: In this context, given that a combination Raf plus MKK1/2 inhibitors (e.g. dabrafenib with trametinib) is the preferred cancer therapy because of the Raf paradox, patients who experience cardiotoxicity from this regime may still benefit from RAF-targeted monotherapy.